 |
|
|
|
 |
|
|
| Article 1 to 10 out of 134 concerning Novartis International AG
|
-
Novartis receives approval in the European Union for Menveo
(22 Mar 2010)
Novartis announced that the European Commission (EC) granted a Marketing Authorization for Menveo® (Meningococcal Group A, C, W135 and Y conjugate vaccine) in all 27 European member states. Menveo is indicated for the active immunization of ...
-
Novartis: Exploratory trial shows no incremental benefit of aliskiren add-on therapy in improving changes to cardiac shape
(17 Mar 2010)
The addition of the cardiovascular medicine aliskiren to standard therapy for patients recovering from a heart attack showed some positive effects in helping limit changes in the heart's shape and function, but did not demonstrate a statistically ...
-
Novartis: NAVIGATOR shows valsartan delayed progression to type 2 diabetes in at-risk cardiovascular patients
(17 Mar 2010)
Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance ...
-
Novartis receives FDA approval of Menveo, a vaccine to prevent meningococcal disease
(24 Feb 2010)
Novartis announced that Menveo® (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine), a quadrivalent meningococcal conjugate vaccine was approved by the US Food and Drug Administration (FDA) for active ...
-
Novartis drug Tasigna receives FDA priority review for newly diagnosed patients with early-stage chronic myeloid leukemia
(23 Feb 2010)
Study results show Tasigna exceeds Glivecin every measure of efficacy in the trial including prevention of disease progression at 12 months
Novartis announced that Tasigna (nilotinib) has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in ...
-
Novartis gains exclusive rights to Debio 025, an antiviral agent as potential first-in-class hepatitis C therapy
(10 Feb 2010)
Novartis to make upfront payment to Debiopharm Group, with Debiopharm eligible for milestones and royalties on future sales
Novartis has gained exclusive rights to develop and market Debio 025 (alisporivir), a potential first-in-class antiviral agent currently in Phase IIb development for the treatment of hepatitis C. Debio 025 is the first in a new class of drugs called ...
-
Imperial Innovations Group licenses Meningitis B vaccine
(28 Jan 2010)
Imperial Innovations Group plc has entered into a licence agreement with Novartis Vaccines and Diagnostics, a division of Novartis. Under the terms of the agreement, Novartis has been granted a worldwide, exclusive licence to the intellectual ...
-
Novartis oral MS therapy FTY720 shows reduced risk of confirmed disability progression
(26 Jan 2010)
Combined data from TRANSFORMS and FREEDOMS studies show significant efficacy in reducing relapses, disability progression and MRI lesions in MS
Results of the TRANSFORMS] and FREEDOMS studies, the two pivotal Phase III clinical trials with oral FTY720 (fingolimod), have been published in The New England Journal of Medicine, providing comprehensive evidence to support the efficacy and safety ...
-
Three new Novartis medicines approved in Japan for patients with type 2 diabetes, high blood pressure and advanced kidney cancer
(22 Jan 2010)
Equa, Exforge and Afinitor provide new treatment options for unmet medical needs
Patients in Japan will benefit from the approval of three new Novartis medicines - Equa® (vildagliptin), marketed as Galvus® in the European Union, for the treatment of type 2 diabetes, Exforge® (valsartan/amlodipine) for high blood pressure, and ...
-
Largest academic-industry collaboration for drug discovery in depression and schizophrenia launched
(21 Jan 2010)
An international consortium of scientists, led by H. Lundbeck A/S and King's College London, has launched one of the largest ever research academic-industry collaboration projects to find new methods for the development of drugs for schizophrenia ...
|
|
|
|
|
Top